RE:RE:RE:RE:RE:Scenarios and speculationThanks to Noteable.
Let us assume this information is widely accepted by big pharma as valid and they have no equivelant alternatives to ONCY for this purpose. Then the data here justifies a very high buyout price for ONCY for this one application alone. That ignores panc, mBC, other applications and other I/O combos.
Show us the money, big pharma!